Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 9:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral Caffeine Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Pharmacodynamics of Cannabinoid-Caffeine Combinations

NCT05478863
View directory record Official record
Conditions
Behavioral Pharmacology of Cannabinoids
Interventions
Oral Placebo, Oral THC, Oral CBD, Oral Caffeine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 25, 2026, 9:40 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

NCT02760615
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn Disease
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 25, 2026, 9:40 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Effects of Dietary Conditions on Drug Response

NCT04315961
View directory record Official record
Conditions
Healthy
Interventions
Blinded drug dose conditions
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 25, 2026, 9:40 AM EDT
Completed Phase 1 Interventional

Examining Caffeine as a Treatment for Antidepressant-induced Arousal Dysfunction in Women

NCT05685407
View directory record Official record
Conditions
Female Sexual Arousal Disorder
Interventions
Caffeine, Placebo
Drug · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 25, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

NCT01001299
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Drug cocktail, RO5185426
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Sep 25, 2026, 9:40 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

NCT04254783
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn's Disease
Interventions
Risankizumab, Cytochrome P450 (CYP) Substrates
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Coronado, California • DeLand, Florida • Margate, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 25, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

NCT01950520
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Propranolol, Pindolol, Dantrolene, Magnesium Sulfate, Caffeine, Qsymia, Topiramate, Phentermine, Naltrexone, Mirabegron 50mg, Mirabegron 200mg, Placebo Cohort 1, Placebo Cohort 2, Placebo for Mirabegron
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 35 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 25, 2026, 9:40 AM EDT
Terminated Phase 3 Interventional Results available

Moderately Preterm Infants With Caffeine at Home for Apnea (MoCHA) Trial

NCT03340727
View directory record Official record
Conditions
Apnea of Prematurity
Interventions
Caffeine Citrate, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
29 Weeks to 33 Weeks
Enrollment
827 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 25, 2026, 9:40 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application

NCT02758990
View directory record Official record
Conditions
Obesity, Rhinitis, Rhinitis, Allergic, Respiratory Sounds, Dyspnea, Headache, Migraine Disorders, Arthritis, Arthralgia, Anxiety, Sleep Initiation and Maintenance Disorders, Sleep Deprivation
Interventions
Vitamin A, Vitamin B6, Vitamin C, Nicotinamide, Vitamin D3, Vitamin E, Broccoli, Spinach, Caffeine, Coffee, Axon Eyewear, Chocolate
Dietary Supplement · Other · Device
Lead sponsor
Verifomics LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Sep 25, 2026, 9:40 AM EDT
Completed Phase 3 Interventional Results available

Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)

NCT00809471
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
placebo, avanafil
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Sep 25, 2026, 9:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Caffeine on Human Spinal Motoneurons

NCT04891393
View directory record Official record
Conditions
Healthy
Interventions
Coffee, Decaffeinated coffee
Dietary Supplement
Lead sponsor
Temple University
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Sep 25, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

Study to Find Out the Optimal Dose of Caffeine in the Combination Tablet of Naproxen Sodium and Caffeine in Patients Experiencing Moderate to Severe Pain After Having Wisdom Teeth Removed

NCT04132336
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Naproxen sodium/Caffeine (BAY2880376), Naproxen sodium (Aleve), Caffeine, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 25, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Results available

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

NCT02688088
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
Drug Cocktail, Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Denver, Colorado • Indianapolis, Indiana • Fairway, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 25, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants

NCT04655040
View directory record Official record
Conditions
Healthy Participants
Interventions
Caffeine, Ritlecitinib
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 25, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine

NCT02128321
View directory record Official record
Conditions
Pharmacokinetics of Repaglinide, Pharmacokinetics of Caffeine, Healthy Subjects
Interventions
Isavuconazole, Repaglinide, Caffeine
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Sep 25, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants

NCT06215430
View directory record Official record
Conditions
Healthy
Interventions
Caffeine Tablet, Omeprazole capsule, Warfarin tablet, Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 25, 2026, 9:40 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

NCT01462318
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Midazolam, Caffeine, S-warfarin, Vitamin K, Omeprazole, Dextromethorphan, BIIB019 (Daclizumab)
Drug · Other · Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Centennial, Colorado • Washington D.C., District of Columbia • Lake Barrington, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 25, 2026, 9:40 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Clinical Effect of Caffeine Consumption in Patients Taking Oral Terbinafine

NCT05667246
View directory record Official record
Conditions
Terbinafine Adverse Reaction
Interventions
Caffeinated Coffee, Decaffeinated Coffee
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 25, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers

NCT06821698
View directory record Official record
Conditions
Healty Volunteers
Interventions
KP-001, Rosuvastatin calcium10mg, Caffeine citrate, Fluvoxamine
Drug
Lead sponsor
Kaken Pharmaceutical
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 25, 2026, 9:40 AM EDT
Active, not recruiting Phase 2 Interventional

Caffeine Use in the Management of Preterm Infants

NCT06327152
View directory record Official record
Conditions
Apnea of Prematurity
Interventions
Caffeine, Sterile Water Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
1 Week to 40 Weeks
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 25, 2026, 9:40 AM EDT
Completed Early Phase 1 Interventional

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

NCT05891119
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Caffeine, Metoprolol, Midazolam, Warfarin, Vitamin K, Omeprazole, Rocatinlimab
Dietary Supplement · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 25, 2026, 9:40 AM EDT
Completed Phase 1 Interventional

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

NCT01517399
View directory record Official record
Conditions
Solid Tumors
Interventions
tivantinib, omeprazole, s-warfarin, caffeine, vitamin K, digoxin, midazolam
Drug · Dietary Supplement
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 25, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect and CYP1A2 Induction Study in Healthy Subjects

NCT02168205
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Pomalidomide, Caffeine, Tobacco
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
40 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Sep 25, 2026, 9:40 AM EDT
Recruiting Phase 2 Interventional

The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

NCT05786066
View directory record Official record
Conditions
Depressive Disorder, Major Depressive Disorder, Bipolar Disorder, Post Traumatic Stress Disorder, Suicidal Ideation
Interventions
Perampanel 6 MG, Ketamine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 25, 2026, 9:40 AM EDT